相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
Michele Fornaro et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2016)
Drugs under early investigation for the treatment of bipolar disorder
George Konstantakopoulos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Golam M. Khandaker et al.
LANCET PSYCHIATRY (2015)
Epigenetic approaches for bipolar disorder drug discovery
Jacob Peedicayil
EXPERT OPINION ON DRUG DISCOVERY (2014)
The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression
C. Lavebratt et al.
MOLECULAR PSYCHIATRY (2014)
Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force
Benicio N. Frey et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2013)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
Putative neuroprotective agents in neuropsychiatric disorders
Seetal Dodd et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
A safe lithium mimetic for bipolar disorder
Nisha Singh et al.
NATURE COMMUNICATIONS (2013)
GABAergic neuroactive steroids: a new frontier in bipolar disorders?
Mauro Giovanni Carta et al.
BEHAVIORAL AND BRAIN FUNCTIONS (2012)
Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder
Sara K. Olsson et al.
BIPOLAR DISORDERS (2012)
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
Jayashri Kulkarni et al.
BMC PSYCHIATRY (2012)
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Matteo Martino et al.
CURRENT NEUROPHARMACOLOGY (2012)
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Konstantinos N. Fountoulakis et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2012)
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
Robert K. McNamara et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression
Brian Leonard et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2012)
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors
Michael Maes et al.
INFLAMMOPHARMACOLOGY (2012)
Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells
Quan Wang et al.
CELL RESEARCH (2011)
Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
Michele Fornaro et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors
M. Berk et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2011)
Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder
I. J. Torres et al.
PSYCHOLOGICAL MEDICINE (2011)
New Drugs for Bipolar Disorder
Marsal Sanches et al.
CURRENT PSYCHIATRY REPORTS (2011)
Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?
Konstantinos N. Fountoulakis et al.
ANNALS OF GENERAL PSYCHIATRY (2011)
Animal models of neuropsychiatric disorders
Eric J. Nestler et al.
NATURE NEUROSCIENCE (2010)
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
Caline S. Karam et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Medicating mood with maintenance in mind: bipolar depression pharmacotherapy
Gin S. Malhi et al.
BIPOLAR DISORDERS (2009)
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
M. De Hert et al.
EUROPEAN PSYCHIATRY (2009)
Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology
G. M. Goodwin
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
S. Leucht et al.
MOLECULAR PSYCHIATRY (2009)
Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study
Jayendra K. Patel et al.
SCHIZOPHRENIA RESEARCH (2009)
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics
Christoph U. Correll et al.
BIPOLAR DISORDERS (2008)
Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder
Yong-Ku Kim et al.
JOURNAL OF AFFECTIVE DISORDERS (2007)
Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder
Galit Shaltiel et al.
CURRENT OPINION IN PHARMACOLOGY (2007)
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Christoph U. Correll et al.
SCHIZOPHRENIA RESEARCH (2007)
Animal models of bipolar disorder and mood stabilizer efficacy: A critical need for improvement
Todd D. Gould et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2007)
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine
Matthew J. Byerly et al.
SCHIZOPHRENIA RESEARCH (2006)
Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches
GM Asnis et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2006)
Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring
M De Hert et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Beyond monoamines: Glutamatergic function in mood disorders
A Kugaya et al.
CNS SPECTRUMS (2005)
The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders
VA Morgan et al.
BIPOLAR DISORDERS (2005)
Incidence and distribution of first-episode mania by age: results from a 35-year study
N Kennedy et al.
PSYCHOLOGICAL MEDICINE (2005)
The genetics of schizophrenia and bipolar disorder: dissecting psychosis
N Craddock et al.
JOURNAL OF MEDICAL GENETICS (2005)
Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder
A Martínez-Arán et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
TD Gould et al.
MOLECULAR PSYCHIATRY (2004)
Atypical antipsychotics and mood stabilization in bipolar disorder
P Brambilla et al.
PSYCHOPHARMACOLOGY (2003)
Age onset of psychotic versus non-psychotic bipolar illness in men and in women
A Yildiz et al.
JOURNAL OF AFFECTIVE DISORDERS (2003)
PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers
HK Manji et al.
MOLECULAR PSYCHIATRY (2002)
分享论文
